Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147312 | 0.86 | TUBB1 (0.46) | NQO2ERN1KDM4EACHEALDH1A1 | |
| SCHEMBL2431072 | 0.86 | TUBB1 (0.42) | NQO2ERN1KDM4EACHEALDH1A1 | |
| SCHEMBL1635785 | 0.84 | ACHE (0.52) | KDM4EACHEALDH1A1MEN1KMT2A | |
| SCHEMBL29793327 | 0.84 | ACHE (0.52) | KDM4EACHEALDH1A1MEN1KMT2A | |
| SCHEMBL8071106 | 0.83 | NQO2 (0.43) | NQO2ERN1KDM4EACHEALDH1A1 | |
| SCHEMBL8762135 | 0.83 | NQO2 (0.43) | NQO2ERN1KDM4EACHEALDH1A1 | |
| SCHEMBL548104 | 0.83 | KDM4E (0.48) | NQO2ERN1KDM4EACHEALDH1A1 | |
| SCHEMBL12533732 | 0.79 | NQO2 (0.41) | NQO2ERN1KDM4EACHEALDH1A1 | |
| SCHEMBL2112642 | 0.79 | MAPT (0.45) | NQO2ERN1KDM4EACHEALDH1A1 | |
| SCHEMBL29869611 | 0.79 | MAPT (0.45) | NQO2ERN1KDM4EACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3507275-A1 | CXCR3 RECEPTOR AGONISTS | Celgene International II Sarl (CH) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
| US-9765067-B2 | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
| CN-1878466-A | Biphenyl derivative or salt thereof, pest control agent containing the same as active ingredient | ISHIHARA SANGYO KAISHA (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1681924-A1 | BIPHENYL DERIVATIVE OR ITS SALT, AND PESTICIDE CONTAINING IT AS AN ACTIVE INGREDIENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006009789-A2 | ARYL-SUBSTITUTED PIPERAZINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | NEUROGEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2005044007-A1 | BIPHENYL DERIVATIVE OR ITS SALT, AND PESTICIDE CONTAINING IT AS AN ACTIVE INGREDIENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2005-05-19 | — | — | WO | disclosed |
| US-20050043556-A1 | 2,2'-Bis(triphenylphosphino)biphenyls complexed with a transition metal-diamine complex; highly active and selective hydrogenation catalysts for the hydrogenation of ketones and imines to alcohols and amines, respectively, used as drug intermediates often required in single isomer form; very low loading | MALAN CHRISTOPHE GUILLAUME (CH) | 2005-02-24 | — | — | US | disclosed |
| EP-1458731-A1 | CHIRAL LIGANDS FOR ASYMMETRIC CATALYSIS | Chirotech Technology Limited (GB) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003048173-A1 | CHIRAL LIGANDS FOR ASYMMETRIC CATALYSIS | CHIROTECH TECHNOLOGY LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| EP-0336123-A2 | New chiral phosphinopyrrolidine compounds and their use for asymmetric synthesis of optically active compounds | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027071-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | NQO2 1202/4885ERN1 238/4885KDM4E 2747/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | NQO2 1609/4885ERN1 4063/4885KDM4E 4161/4885 |
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | MCHR1, MCHR2, PRLHR | NQO2 2670/4885ERN1 4696/4885KDM4E 1610/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | NQO2 1609/4885ERN1 4063/4885KDM4E 4161/4885 |
| US-20050043556-A1 | 2,2'-Bis(triphenylphosphino)biphenyls complexed with a transition metal-diamine complex; highly active and selective hydrogenation catalysts for the hydrogenation of ketones and imines to alcohols and amines, respectively, used as drug intermediates often required in single isomer form; very low loading | ADH5, ADH1A, ADH1C | NQO2 2654/4885ERN1 2001/4885KDM4E 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.